eZ+;Mt ~! i |g~3Bgm M8R0ffCAf0A ,AtIO C 5bc8} pGtNmWS9D !=FdF]dY+F+F ML3N Uot|RUlUo A& ,fzv)Mz% 2Cy5 xQ6\MjQ=exQPx\n@*xH G0!0f exD9HSe \XaEE!fX%{f 6@}1@Hb0-NH066 4*I*i@}*/f} @XJ~XgZW n|SS?oSSE. :YI Ae8[9D8 Zs Fue Cc\ }x[^~ g+g9M=8= FP 0-eF F$__? ~b^ gzG}GW0GZ )S 5l/6 h\z~y bF[.

Zanubrutinib demonstrated significantly higher overall response (ORR) and superior progression-free survival (PFS) over ibrutinib in patients with R/R CLL/SLL. This PFS benefit was reported across all major subgroups, including the del(17p)/K&Y3mut population. Zanubrutinib has a favorable safety profile compared with ibrutinib, including a lower rate of grade ≥3 and serious adverse events (AEs) as well as fewer AEs leading to treatment discontinuation and dose reductions. Zanubrutinib has a better cardiac profile than ibrutinib with lower rates of atrial fibrillation, serious cardiac events, cardiac events leading to treatment discontinuation, and fewer fatal cardiac events.